SeekingAlpha · Aug 12, 2026
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests the company's drug Lupkynis. Read more on AUPH stock here.
NASDAQ · AUPH
Aurinia Pharmaceuticals Inc.
Healthcare · Biotechnology
$16.65
Down-$0.62 (-3.59%)
Updated Aug 22, 2026, 10:38 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.1B
- P/E ratio
- 28.02
- Dividend yield
- 0.00%
- 52-week range
- $13.82 – $19.25
- Volume
- 1.25M
- Avg. volume
- 1.77M
Price performance
AUPH price history
1M range · 21 trading sessions · Daily adjusted prices
AUPH closed at $16.65 after 21 trading sessions, up 8.47% for the selected period.
- Last close
- $16.65
- Period change
- +8.47%
- Period low
- $14.57
- Period high
- $17.27
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $17.20 | $17.32 | $16.625 | $16.65 | 1.25M |
| Aug 20, 2026 | $16.60 | $17.80 | $16.60 | $17.27 | 2.64M |
| Aug 19, 2026 | $15.57 | $16.175 | $15.3397 | $16.17 | 1.65M |
| Aug 18, 2026 | $15.29 | $15.36 | $15.1501 | $15.30 | 718.43K |
| Aug 17, 2026 | $15.42 | $15.59 | $15.07 | $15.29 | 1M |
| Aug 14, 2026 | $15.09 | $15.49 | $14.9008 | $15.47 | 827.25K |
| Aug 13, 2026 | $15.56 | $15.56 | $15.015 | $15.18 | 1.59M |
| Aug 12, 2026 | $15.405 | $15.58 | $15.21 | $15.45 | 854.45K |
| Aug 11, 2026 | $15.50 | $15.59 | $15.31 | $15.37 | 730.73K |
| Aug 10, 2026 | $15.70 | $15.945 | $15.42 | $15.45 | 1.05M |
| Aug 7, 2026 | $16.26 | $16.59 | $15.60 | $15.85 | 1.55M |
| Aug 6, 2026 | $15.93 | $16.35 | $15.702 | $16.13 | 2.24M |
| Aug 5, 2026 | $15.05 | $15.24 | $14.89 | $15.19 | 1.03M |
| Aug 4, 2026 | $14.81 | $15.005 | $14.60 | $14.93 | 980.98K |
| Aug 3, 2026 | $14.72 | $14.895 | $14.515 | $14.57 | 1.4M |
| Jul 31, 2026 | $14.80 | $15.25 | $14.3628 | $14.88 | 1.66M |
| Jul 30, 2026 | $15.10 | $15.135 | $14.74 | $15.00 | 1.08M |
| Jul 29, 2026 | $14.95 | $15.28 | $14.85 | $15.18 | 884.15K |
| Jul 28, 2026 | $15.24 | $15.3812 | $14.90 | $14.96 | 1.71M |
| Jul 27, 2026 | $15.47 | $15.77 | $15.20 | $15.22 | 1.06M |
| Jul 24, 2026 | $15.41 | $15.52 | $15.13 | $15.35 | 792.97K |
Latest AUPH news
The latest Smart Investors Daily articles mentioning AUPH.
Stock researchCompany · Overview
AUPH research
Overview
Company profile and research snapshot.
Company profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Sector Perform | — |
| Dec 3, 2025 | Leerink Partners | Market Perform | — |
| Nov 7, 2025 | Jefferies | Buy | — |
| Nov 5, 2025 | RBC Capital | Sector Perform | — |
| Aug 1, 2025 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16
RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Sector Perform and raises the price target from $15 to $16.
Benzinga · Aug 6, 2026
Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $323.065 million estimate.
Benzinga · Aug 6, 2026
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.24 by 16.67 percent. This is a 75 percent increase over earnings of $0.16 per share
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
